RT Journal Article
SR Electronic
T1 MHRA Drug Safety Update: denosumab (Xgeva) and rebound hypercalcaemia
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 142
OP 142
DO 10.1136/dtb.2018.11.000040
VO 56
IS 12
YR 2018
UL http://dtb.bmj.com/content/56/12/142.abstract
AB Review of: Medical and Healthcare products Regulatory Agency. Denosumab for giant cell tumor of bone: risk of clinically significant hypercalcaemia following discontinuation. Drug Safety Update 2018;11(11);2.